Business Context and Reporting Period
Company: Damora Therapeutics, Inc. (formerly Galecto, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: A preclinical-stage biopharmaceutical company developing therapies for hematological malignancies, specifically myeloproliferative neoplasms (MPNs). The company focuses on a portfolio of mutant calreticulin (mutCALR) targeting product candidates: DMR-001, DMR-002, and DMR-003. In November 2025, the company completed an asset acquisition of "Pre-Acquisition Damora" and executed a significant PIPE transaction.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(27,783) | $(2,533) |
| Operating Expenses | $30,811 | $2,599 |
| Research & Development (R&D) | $23,777 | $678 |
| General & Administrative (G&A) | $7,034 | $1,921 |
| Cash and Cash Equivalents (End of Period) | $532,899 | $11,939 |
| Net Cash Used in Operating Activities | $(20,598) | $(2,439) |
| Net Cash Provided by Financing Activities | $295,921 | $0 |
| Accumulated Deficit | $(515,146) | $(280,057) |
Material Changes vs. Prior Period
- Significant Increase in Expenses: Total operating expenses increased by 1,085% year-over-year, driven primarily by R&D costs which rose 3,407%. This increase is attributed to the November 2025 asset acquisition, the initiation of the Paragon Option Agreement, and the amortization of the Paramora warrant obligation ($5.0 million).
- Liquidity Expansion: Cash and cash equivalents increased by $275.3 million, primarily due to a February 2026 underwritten public offering that generated approximately $295.5 million in net proceeds.
- Capital Structure Changes: Following stockholder approval in February 2026, 42,005 shares of Series C Preferred Stock were automatically converted into 42,005,000 shares of Common Stock. The company also increased its authorized common stock from 300 million to 500 million shares.
- Portfolio Strategy Shift: In March 2026, the company deprioritized the development of GB3226 to focus exclusively on its mutCALR portfolio (DMR-001, DMR-002, DMR-003).
Guidance, Outlook, and Risks
- Development Timeline: The company intends to make its first regulatory submission for DMR-001 in mid-2026, with a global Phase 1/1b trial initiation expected thereafter. DMR-002 submission is targeted for the second half of 2026, and DMR-003 for 2027.
- Liquidity Outlook: Management believes existing cash resources ($532.9 million as of March 31, 2026) are sufficient to fund operations into 2029. However, the company expects to continue incurring losses and will require additional financing in the future.
- Key Risks:
- Preclinical Stage: No products have been approved or administered to humans; success is not guaranteed.
- Third-Party Reliance: Significant reliance on Paragon Therapeutics for research and development under the Paragon Option Agreement, including potential milestone payments up to $22.0 million.
- Regulatory and Manufacturing: Risks associated with FDA approval, clinical trial enrollment, and reliance on third-party contract manufacturers (including potential impacts from the BIOSECURE Act regarding Chinese suppliers).
- Capital Requirements: Failure to raise additional capital could force delays or termination of clinical trials.
Investor Verification Checklist
- Capital Runway: Verify the accuracy of the "into 2029" funding projection given the rapid increase in quarterly burn rate ($20.6 million operating cash burn in Q1 2026).
- Paragon Agreement Terms: Review the specific milestones and payment triggers under the Paragon Option Agreement, particularly the $22.0 million potential liability and the $5.0 million non-cash warrant expense recognized in Q1.
- Regulatory Milestones: Monitor the mid-2026 timeline for the Investigational New Drug (IND) submission for DMR-001.
- ATM Program Utilization: Track the usage of the $150 million At-The-Market (ATM) offering program, noting that $29.4 million was raised in May 2026 (subsequent to the quarter end).
- Preferred Stock Conversion: Confirm the status of remaining Series C Preferred Stock and any future conversion events that may impact common share dilution.